EX-99.1 2 dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

Press Release

I-many Reports Fourth Quarter and Year-End 2006 Financial Results

EDISON, N.J., February 13, 2006 — I-many, Inc. (NASDAQ:IMNY), the leading provider of advanced Contract Lifecycle Management (CLM) solutions for managing corporate commitments, reported financial results for the fourth quarter and year ended December 31, 2006.

Q4 2006 Financial Highlights

 

   

Net revenues increased over Q3 2006 to $7.6 million

 

   

Gross value of license contracts signed up 129% vs. Q3 2006

 

   

Net revenues from subscriptions up 96% over Q4 2005

 

   

Unamortized software subscriptions up 72% over Q4 2005 to a record $14.8 million

 

   

Deferred revenue and unamortized software subscriptions at record $30.8 million, up 50% vs. Q4 2005

GAAP Financial Results

On a GAAP basis, net revenues for the quarter totaled $7.6 million, an increase of 1.6% from $7.5 million reported in the prior quarter, and a decrease of 7.7% from $8.3 million reported for the fourth quarter of 2005. Net loss for the quarter was $(0.09) per share, as compared to a net loss of $(0.08) per share in the previous quarter and $(0.04) per share in the fourth quarter of 2005.

For the year ended December 31, 2006, net revenues totaled $29.6 million, a decrease of 9.2% from $32.6 million reported in the previous year. Net loss for 2006 was $(0.33) per share, versus a net loss of $(0.21) per share in 2005.

Net revenues and loss exclude the portion of the gross value of license and service contracts booked during the quarter which the company cannot realize until future periods, including those related to the increasing number of multi-year software subscriptions. For a more complete picture of the company’s performance, see the discussion of non-GAAP financial results, below.

Quarter-end cash, restricted cash and short-term investments totaled $17.7 million, as compared to $13.3 million at the end of the previous quarter and $17.4 million at the end of 2005. The increase in cash is due to a $7 million financing ($6.5 million, net of expenses) completed during the quarter, offset by operating losses.

Non-GAAP Financial Results

Management believes certain non-GAAP financial results may present a useful picture of the company’s progress as it continues to change its licensing mix to include more software subscriptions. This includes the gross value of license contracts signed, or “bookings,” which totaled $4.0 million during the fourth quarter. This represents an increase of 129% from $1.8 million signed in the prior quarter and approximately the same as $4.1 million signed in the fourth quarter of 2005. For the year, bookings totaled $14.4 million, up 3% from $14.0 million in 2005.

These contracts brought the total amount of unamortized software subscriptions to be recognized over the next five years to a record $14.8 million, up 16% from $12.7 million reported at the end of the prior quarter, and an increase of 72% from $8.6 million at end of the fourth quarter 2005.

The combined amount of deferred revenue and unamortized software subscriptions at December 31, 2006 reached a record $30.8 million, an increase of 17% from $26.4 million in the prior quarter, and up 50% from $20.6 million at the end of the fourth quarter 2005.

 

Page 4 of 10


I-many introduced its subscription offering in the second quarter of 2004 in order to pursue certain benefits for both customers and the company. Management believes subscriptions expand the market to customers that find regular subscription payments an easier and more flexible implementation of CLM, and they have the potential to provide I-many smoother and more predictable revenue growth.

Reflecting the increasing contribution of subscription revenue, the amount of product revenue generated from subscription contracts sold in prior periods and recorded in the fourth quarter reached a record level of $708 thousand up 4% from $678 thousand in the prior quarter, and up 96% from $361 thousand reported in the fourth quarter of 2005.

The combined amount of recurring revenue from maintenance and support, hosting and subscriptions totaled $15.9 million in 2006, an increase of 16% from $13.6 million in 2005.

Other Q4 2006 Highlights

Significant events during the fourth quarter of 2006 included:

 

   

11 new license transactions exceeding $50 thousand in gross value were signed during the quarter, up from five in the previous quarter and compared to 12 in the same period a year ago. These new transactions averaged approximately $369 thousand in gross value. Two new enterprise customers were in the company’s Life Sciences market segment.

 

   

AVANIR Pharmaceuticals, a leading provider of therapeutic products for treating chronic diseases, licensed I-many’s latest generation CLM solution for Life Sciences (I-many Medicaid™, I-many CARS™, and I-many Validata™) to cost-effectively and accurately manage the complexities of Medicaid and managed care contracts.

 

   

Talecris Biotherapeutics completed the implementation of three I-many products, I-many CARS®, I-many Medicaid™, and I-many Government Pricing™, in order to optimize its revenues associated with rebates, chargebacks, and accurate pricing, while also ensuring compliance with a range of regulations including Medicaid and the Deficit Reduction Act (DRA).

 

   

A Top 15 US pharma company with more than 3,000 employees signed a five-year licensing agreement for the next generation of I-many CARS, I-many Medicaid and I-many Government Pricing when released, and I-many Validata.

 

   

Dr. Reddy’s Laboratories, A NYSE-traded global pharmaceutical company, has signed a five-year agreement to license the next generation of I-many CARS (when released), along with I-many Contract Manager. The commitment is a key element in its ongoing drive to optimize its more than $1 billion in annual revenues and increase its market share in the U.S.

 

   

A new pharmaceutical company formed to market third-party branded pharmaceutical products has licensed I-many CARS®, I-many Medicaid™, and I-many Government Pricing™. These solutions will provide critical components to its operational infrastructure and will be used to support sales resulting from a recent $800+ million acquisition of branded pharmaceutical products.

 

   

Sales to existing Fortune 100 clients in the company’s Industry Solution segment included another subscription for I-many Contract Manager by a major Aerospace and Defense company and a long-time non-Life Sciences customer and product development partner, to bring the benefits of I-many’s Contract Lifecycle Management to another company division that designs and produces automotive products.

 

   

A private placement funding of $7 million ($6.5 million, net of expenses) was completed. It was subscribed at market value by both new and existing shareholders and substantially strengthened the company’s balance sheet in preparation for sales growth initiatives targeting large enterprise customers.

 

   

I-many was named the largest “pure play” contract lifecycle management vendor in the software industry by Software Magazine. This marks the third consecutive year that I-many has been included in Software Magazine’s Software 500 list.

“I-many continued to be the recognized industry leader in 2006 as it introduced, sold, and delivered products based on its new state-of-the-art CLM platform,” said John A. Rade, I-many’s chairman, president and CEO. “A year highlighted by major milestones and achievements was topped off in the final quarter by a flurry of new contract wins. The number of new deals was more than double over last quarter, showing the demand for CLM and compliance is increasing and companies are looking to I-many for the most comprehensive and capable solution. This allowed us to exceed our guidance for gross value license contracts for the year. We’ve also seen a continued expansion of subscription-based licenses, with virtually all of our bookings this quarter coming in as subscriptions. While this had made it difficult to successfully predict the growth in our GAAP net revenues and we fell short at year’s end, subscriptions have provided I-many an investment with greater and more predictable long-term payoffs.”

 

Page 5 of 10


2007 Guidance

 

   

GAAP Net Revenue: $35-40 million, of which approximately $18 million will come from recurring revenue (Subscription, Maintenance and Support, and Hosting). However, it is difficult to predict the mix of recognizable and deferred transactions the company will sign, and this could substantially affect the amount of GAAP net revenue reported in any given period.

 

   

Gross value of new license transactions: at least $16 million.

 

   

Cash at year-end: $11-13 million.

“In addition to subscriptions, building new applications running on the new CLM platform has been another area of significant investment,” noted Rade, “making our R&D expenses nearly double industry averages at more than 40% of net revenue this quarter. R&D investment will continue into a good part of 2007, but we see this level coming down substantially as these projects end and unlock excellent revenue and profit potential over the next few years. The combination of these two major factors - investments in R&D and the transition to subscriptions – has created an unmatched competitive advantage that is supported by a healthy balance sheet. More work lies ahead on our Contract Manager product to fill out its feature set on the new CLM platform; however, our efforts on all of our products have resulted in a strong pipeline of product advancements and pending license sales that will position us well in our efforts to achieving our new goals for 2007 and beyond.”

Conference Call

I-many will host a conference call to discuss its fourth quarter and year-end 2006 results later today at 4:30 p.m. Eastern Time. The dial-in number for the conference call is 1-866-543-6411 or 1-617-213-8900, passcode #70461923.

The call is also being webcast, and can be accessed via I-many’s web site at www.imany.com.

A replay of the call will be available after 6:30 p.m. on the same day and until February 20, 2007, and can be accessed by dialing 1-888-286-8010 or 1-617-801-6888, conference ID #54037744.

Use of Non-GAAP Financial Information

The company supplements its GAAP financial statements in this release and in its annual report on Form 10-K with a reconciliation of the non-GAAP gross value of license transactions to its reported GAAP product revenues. This non-GAAP financial information is provided as additional information for investors and is not in accordance with or an alternative to GAAP. Following the balance sheet and income statement, management has included a table that shows the results for the fourth quarter and the full year 2006 compared to the comparable periods in 2005 for new license transactions including subscription contracts, the recognition into reportable revenue of subscriptions and other deferred transactions, and the reconciliation of those numbers to total product revenue according to generally accepted accounting principles (“GAAP”). Management believes its inclusion can enhance an overall understanding of the company’s past operational performance and also its prospects for the future. This reconciliation of product revenues is made with the intent of providing both management and investors a more complete understanding of the future revenue opportunities for the company, as opposed to GAAP revenue results, which do not include the impact of newly-executed subscription agreements and other deferred revenue arrangements that are material to the ongoing performance of the company’s business. This information quantifies the various components comprising current revenue, which in each quarter consists of revenues from licenses sold in current periods plus revenues deferred from prior periods, less revenue deferred from licenses sold in current periods. Management uses this information as a basis for planning and forecasting core business activity in future periods and believes it is useful in understanding our results of operations. The presentation of this additional revenue information is not meant to be considered in isolation or as a substitute for revenues reported in accordance with generally accepted accounting principles in the United States.

About I-many

I-many (NASDAQ:IMNY) is the leading provider of advanced Contract Lifecycle Management solutions for managing corporate commitments. Designed to extend beyond the traditional contract management capabilities, I-many ContractSphere® offers an end-to-end solution, from pre-contract processes and

 

Page 6 of 10


contract management to transaction compliance. Ultimately, this provides companies with the visibility and control needed to manage any type of commitment - from contracts and obligations to payments and collections. The result is increased revenue, minimized risk and dramatically reduced operating costs, which deliver improved profitability with hard return on investment. More than 280 customers across 21 industries worldwide have implemented and realized the value of I-many business solutions. For more information, please visit www.imany.com.

This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include: the risk of unforeseen technical or practical impediments to planned software development, which could affect the company’s product release timetable; the risk that the ratio of subscription license sales to perpetual license sales could be higher than anticipated, possibly leading to lower GAAP revenue in current periods and less cash than predicted in the near term; the risk of lower demand for our new products than we anticipate; the inherent risks of large software implementation projects, which can cause customer disagreements that could affect I-many’s ability to collect both services and license revenue, whether recognized or deferred; the possibility that customers could cancel maintenance and support services at the time of annual renewal, which could decrease I-many’s base of recurring revenue; the possibility that extraordinary events outside the company’s control could extend the length of the sales cycle for the company’s products or make the market for the company’s products more unpredictable; the risk that the company will not be successful in opening new markets for its products; and other risk factors set forth from time to time in the company’s filings with the Securities and Exchange Commission.

 

Page 7 of 10


I-MANY, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(Unaudited)

 

     Three months ended
December 31,
    Twelve months ended
December 31,
 
     2006     2005     2006     2005  

Net Revenues:

        

Product

   $ 756     $ 2,155     $ 3,954     $ 6,279  

Services

     6,835       6,071       25,621       26,297  
                                

Total net revenues

     7,591       8,226       29,575       32,576  

Operating expenses:

        

Cost of third-party technology

     24       225       269       520  

Cost of services

     4,525       3,400       16,940       14,764  

Amortization of acquired intangible assets

     46       343       482       1,384  

Sales and marketing

     2,669       2,449       9,323       8,626  

Research and development

     3,186       2,540       12,585       11,267  

General and administrative

     1,396       1,206       5,449       4,819  

Depreciation

     245       205       824       796  

Restructuring and other charges (credits)

     35       15       103       (10 )
                                

Total operating expenses

     12,126       10,383       45,975       42,166  
                                

Loss from operations

     (4,535 )     (2,157 )     (16,400 )     (9,590 )

Other income, net

     168       103       585       285  
                                

Net loss

   ($ 4,367 )   ($ 2,054 )   ($ 15,815 )   ($ 9,305 )
                                

Basic and diluted net loss per common share

   ($ 0.09 )   ($ 0.04 )   ($ 0.33 )   ($ 0.21 )
                                

Weighted average shares outstanding

     49,841       46,340       47,782       44,548  
                                

 

Page 8 of 10


I-MANY, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands)

 

     December 31,
     2006    2005

Assets

     

Current Assets:

     

Cash and cash equivalents

   $ 17,232    $ 16,805

Restricted cash

     80      —  

Accounts receivable

     8,120      9,577

Other current assets

     766      845
             

Total current assets

     26,198      27,227

Property and equipment, net

     1,341      1,188

Restricted cash

     427      555

Other assets

     121      122

Acquired intangible assets, net

     231      713

Goodwill

     8,667      8,667
             

Total assets

   $ 36,985    $ 38,472
             

Liabilities and Stockholders’ Equity

     

Current liabilities:

     

Accounts payable and accrued expenses

   $ 7,224    $ 5,618

Current portion of deferred revenue

     15,773      12,194

Current portion of capital lease obligations

     154      8
             

Total current liabilities

     23,151      17,820

Deferred revenue, net of current portion

     1,256      1,242

Other long-term liabilities

     1,124      1,054

Stockholders’ equity

     11,454      18,356
             

Total liabilities and stockholders’ equity

   $ 36,985    $ 38,472
             

 

Page 9 of 10


Reconciliation of Gross Value of License Bookings to Reportable Product Revenue

 

     Three months ended
December 31
   Twelve months ended
December 31
     2006    2005    2006    2005
     (AMOUNTS IN THOUSANDS)

Gross value of license contracts sold:

           

Health and Life Sciences

   $ 3,789    $ 3,912    $ 12,435    $ 11,442

Industry Solutions

     232      155      1,967      2,582
                           
     4,021      4,067      14,402      14,024

Add product revenue recorded in current period from contracts sold in prior periods:

           

Health and Life Sciences - subscriptions

     637      326      2,179      926

Health and Life Sciences - other deferrals

     0      0      0      1,476

Industry Solutions - subscriptions

     71      35      176      35
                           
     708      361      2,355      2,437

Less value of license contracts sold in current period and deferred to future periods:

           

Health and Life Sciences

     3,754      2,221      10,889      8,464

Industry Solutions

     219      52      1,914      1,718
                           
     3,973      2,273      12,803      10,182

Product revenue recorded:

           

Health and Life Sciences

     672      2,017      3,725      5,380

Industry Solutions

     84      138      229      899
                           
   $ 756    $ 2,155    $ 3,954    $ 6,279
                           

Note: I-many has updated the definition of “Gross Value of License Contracts” signed to include first year maintenance and support sold with new traditional perpetual licenses. Management believes this presents a more comparable number to subscriptions that include maintenance and support as part of the subscription fee paid. The results have been updated with this definition for both the current and comparable periods.

Company Contacts

I-many, Inc.

Kevin Harris, CFO

732-452-1515

kharris@Imany.com

or

Investor Relations:

Liolios Group, Inc. 949-574-3860

Ron Both, ron@liolios.com

Geoffrey Plank, geoffrey@liolios.com

###

 

Page 10 of 10